Mersana Therapeutics Presents New Preclinical Data on XMT-1536 at the International Association for the Study of Lung Cancer (IASLC) 19th World Conference on Lung Cancer
Novel Immunohistochemistry Assay Distinguishes Non-Small Cell Lung Cancer (NSCLC) Subtypes
XMT-1536 Phase 1 Dose Escalation Ongoing With Data Reporting in the First Half of 2019
Details of the presentation are as follows:
Title: MERS67 is a Novel anti-NaPi2b Antibody and Demonstrates Differential Expression Patterns in Lung Cancer Histologic Subtypes
Poster Session: P2.09 Pathology, Poster 24
“We continue to be gratified with the progress this program has made, and the data indicate how best to use immunohistochemistry as a means to characterize tumors and identify patients,” said
Mersana’s poster presentation at IALSC WCLC 2018 evaluated the proprietary immunohistochemistry reagent (MERS67) for its ability to quantify NaPi2b expression in lung adenocarcinoma (ACA) versus lung squamous cell carcinoma (SqCC). Within a tumor tissue microarray, 99 individual cases were evaluable. By morphologic classification 63 cases were SqCC and 23 cases were ACA. Using a cut point of H=50, there was a statistically significant difference in the number of NaPi2b positive ACA cases (19/23) vs SqCC (3/63). Among 43 cases where p40 and TTF-1 were evaluable and were in agreement with morphologic diagnosis, 7/7 cases of ACA were positive for NaPi2b, while 0/36 SqCC were positive. This study was done in collaboration with the
Stern Investor Relations, Inc.
Source: Mersana Therapeutics, Inc.